Targeting KRAS: The Elephant in the Room of Epithelial Cancers

Targeting KRAS: The Elephant in the Room of Epithelial Cancers

Mutations of the proto-oncogene KRAS are the most frequent gain-of-function alterations found in cancer. KRAS is mutated in about 30% of all human tumors, but it could reach more than 90% in certain cancer types such as pancreatic adenocarcinoma. Although historically considered to be undruggable, a...

Full description

Bibliographic Details
Main Authors: Valeria Merz, Marina Gaule, Camilla Zecchetto, Alessandro Cavaliere, Simona Casalino, Camilla Pesoni, Serena Contarelli, Fabio Sabbadini, Monica Bertolini, Domenico Mangiameli, Michele Milella, Vita Fedele, Davide Melisi
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
KRAS
NSCLC
pancreatic cancer
colon cancer
G12C mutation
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.638360/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.638360/full

Similar Items